Prevalso

Prevalso is a medication used to treat acute migraine attacks. It is a selective serotonin and dopamine receptor agonist, which allows it to exert its effects on the body without activating other types of receptors that could lead to unpleasant side effects.

The primary mechanism of action of Prevalso involves the agonist activity at serotonin 5-HT1 receptor sites on vascular smooth muscle cells and sensory nerve terminals. This action leads to a reduction in the release of pro-inflammatory neuropeptides and the inhibition of pro-inflammatory neuropeptide release from nerve terminals. As a result, Prevalso causes vasodilatation and reduces the sensitivity of afferent nerve fibers, thereby decreasing the frequency and severity of migraine attacks.

The efficacy of Prevalso in treating acute migraine attacks has been demonstrated in several clinical trials. In these studies, Prevalso has been shown to be effective in reducing the frequency and severity of migraine attacks, as well as improving the quality of life for patients suffering from this condition.

Prevalso is administered via an intranasal spray. The recommended dosage is 5 mg to 10 mg given once, as often as every 2 hours as needed, up to a maximum of 2 times in any 24-hour period. When used correctly, Prevalso has been shown to be well-tolerated by most patients, although some may experience side effects such as nausea, ^{^ 100} injection site reactions, or facial flushing.